Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial
David L. Clark, Bill Cavanagh, Alan L. Shields, Paul Karpecki, John D. Sheppard, Todd C. Brady
Topics & Concepts
MedicineTolerabilityAllergic conjunctivitisItchingClinical endpointAdverse effectRandomized controlled trialAllergenClinical trialDermatologyIrritationAllergyInternal medicineImmunologyOcular Surface and Contact LensOcular Infections and TreatmentsCorneal Surgery and Treatments